Mostrando postagens com marcador Genetics. Mostrar todas as postagens
Mostrando postagens com marcador Genetics. Mostrar todas as postagens

quarta-feira, 1 de outubro de 2014

Disease decoded: Gene mutation may lead to development of new cancer drugs

 


The discovery of a gene mutation that causes a rare premature aging disease could lead to the development of drugs that block the rapid, unstoppable cell division that makes cancer so deadly.

Scientists at the University of Michigan and the U-M Health System recently discovered a protein mutation that causes the devastating disease dyskeratosis congenita, in which precious hematopoietic stem cells can't regenerate and make new blood. People with DC age prematurely and are prone to cancer and bone marrow failure.

But the study findings reach far beyond the roughly one in 1 million known DC patients, and could ultimately lead to developing new drugs that prevent cancer from spreading, said Jayakrishnan Nandakumar, assistant professor in the U-M Department of Molecular, Cellular, and Developmental Biology.

The DC-causing mutation occurs in a protein called TPP1. The mutation inhibits TPP1's ability to bind the enzyme telomerase to the ends of chromosomes, which ultimately results in reduced hematopoietic stem cell division. While telomerase is underproduced in DC patients, the opposite is true for cells in cancer patients.

"Telomerase overproduction in cancer cells helps them divide uncontrollably, which is a hallmark of all cancers," Nandakumar said. "Inhibiting telomerase will be an effective way to kill cancer cells."

The findings could lead to the development of gene therapies to repair the mutation and start cell division in DC patients, or drugs to inhibit telomerase and cell division in cancer patients. Both would amount to huge treatment breakthroughs for DC and cancer patients, Nandakumar said.

Nandakumar said that a major step moving forward is to culture DC patient-derived cells and try to repair the TPP1 mutation to see if telomerase function can be restored. Ultimately, the U-M scientist hopes that fixing the TPP1 mutation repairs telomerase function and fuels cell division in the stem cells of DC patients.

"It's conceivable that with the recent advancement in human genome-editing technology, we could, in the not-so-distant future, repair the mutation in hematopoietic stem cells in the bone marrow of DC patients," Nandakumar said.

The findings also reinforce how one tiny change in an amino acid chain can cause devastating health consequences.

"It was surprising to us that just deleting one single amino acid in a protein chain that is 544 amino acids long can result in such a severe disease," Nandakumar said.


Story Source:

The above story is based on materials provided by University of Michigan. The original article was written by Laura Bailey. Note: Materials may be edited for content and length.


Journal Reference:

  1. H. Kocak, B. J. Ballew, K. Bisht, R. Eggebeen, B. D. Hicks, S. Suman, A. O'Neil, N. Giri, I. Maillard, B. P. Alter, C. E. Keegan, J. Nandakumar, S. A. Savage. Hoyeraal-Hreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1. Genes & Development, 2014; DOI: 10.1101/gad.248567.114

 

sexta-feira, 4 de julho de 2014

Sweet genes: New way found by which metabolism is linked to the regulation of DNA


A research team at the Faculty of Medicine & Dentistry at the University of Alberta have discovered a new way by which metabolism is linked to the regulation of DNA, the basis of our genetic code. The findings may have important implications for the understanding of many common diseases, including cancer.

The DNA wraps around specialized proteins called histones in the cell's nucleus. Normally, histones keep the DNA tightly packaged, preventing the expression of genes and the replication of DNA, which are required for cell growth and division. In order for these critical functions to take place, histones need to be modified with the attachment of an acetyl-group, donated by a critical molecule called acetyl-CoA. This attachment relaxes the DNA, allowing for DNA replication and gene expression. This mechanism is called "epigenetic regulation of DNA" and is important for normal functions (like the growth of an embryo or brain functions) or in common diseases like heart failure or cancer. Until now, how the nucleus generates acetyl-CoA for histone acetylation had remained elusive.

The research team, lead by postdoctoral fellow Gopinath Sutendra and professor Evangelos Michelakis in the Department of Medicine, discovered that an enzyme thought to reside only within mitochondria, called Pyruvate Dehydrogenase Complex (PDC), can actually find its way into the nucleus and do what it is designed to do in the mitochondria: generate acetyl-CoA. When in mitochondria, PDC uses the carbohydrates from our diet to generate acetyl-CoA for energy production. When in the nucleus, PDC can produce acetyl-CoA for histone acetylation.

"Although this jumping of an enzyme from one organelle into another in the cell is not unheard off, our results were quite surprising," Sutendra says. "We wanted to measure acetyl-CoA levels and PDC in the mitochondria because that's where we thought they were. But accidentally we had the nuclei isolated at the same time and we saw PDC in the nucleus. So we asked, 'what is PDC doing there?' And that started it all."

"We were surprised that, despite the recognized importance of histone acetylation in cell biology and medicine, and despite the efforts by many to develop drugs that regulate histone acetylation, the source of acetyl-CoA in the nucleus had remained unknown," Michelakis says. "Sometimes the answers to important biological questions are just next to you, waiting to be discovered," he adds.

The team found that the translocation of PDC into the nucleus made cancer cells grow faster, an observation that may lead to additional strategies in the war against cancer. Yet, because the findings relate to how our DNA is regulated in general, this work may have far broader implications for many physiologic or pathologic conditions where epigenetic regulation is critical. "We are very excited about this new pathway linking energy production (the process known as metabolism) with gene regulation," the researchers say.

The work is published in the July 3, 2014, issue of the journal Cell. Michelakis is particularly proud of the fact that this is the product of a team that is entirely based at the University of Alberta. Many young researchers in the Department of Medicine like Adam Kinnaird, Peter Dromparis and Roxane Paulin were critical members of the team that also included technicians (Trevor Stenson, Alois Haromy, Kyoko Hashimoto) and researchers from the NanoFAB facility (Nancy Zhang, Eric Flaim)

. The work was funded by the Canadian Institutes for Health Research and the Hecht Foundation (Vancouver, Canada).


Story Source:

The above story is based on materials provided by University of Alberta Faculty of Medicine & Dentistry. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gopinath Sutendra, Adam Kinnaird, Peter Dromparis, Roxane Paulin, Trevor H. Stenson, Alois Haromy, Kyoko Hashimoto, Nancy Zhang, Eric Flaim, Evangelos D. Michelakis. A Nuclear Pyruvate Dehydrogenase Complex Is Important for the Generation of Acetyl-CoA and Histone Acetylation. Cell, 2014; 158 (1): 84 DOI: 10.1016/j.cell.2014.04.046

sábado, 14 de junho de 2014

Involving a genetic health care professional may improve quality, reduce unnecessary testing

 


A new Moffitt Cancer Center study published Thursday in Genetics in Medicine shows that counseling from a genetic health care provider before genetic testing educates patients and may help reduce unnecessary procedures.

Up to 10 percent of cancers are inherited, meaning a person was born with an abnormal gene that increases their risk for cancer. "Pre-test genetic counseling in which a health care provider takes a thorough family history and discusses the potential risks and benefits of genetic testing is standard of care as recommended by the American Society of Clinical Oncology and National Society of Genetic Counselors," said Tuya Pal, M.D., a board-certified geneticist at Moffitt and senior author of the paper.

In the Moffitt study, researchers surveyed 473 patients who had genetic testing for BRCA1 and BRCA2 gene mutations, which are associated with an increased risk of breast and ovarian cancers. Among study participants who saw a board-certified geneticist or genetic counselor, almost all recalled having a pre-test discussion, compared to only 59 percent of those who did not. These findings suggest large differences in quality of care across providers who order testing.

The researchers also suggest there may be cost-of-care implications when genetic health care providers are involved. "Our results suggest that genetic health care providers are less likely to order more expensive comprehensive genetic testing, when less expensive testing may be appropriate," said Deborah Cragun, Ph.D., lead study author and post-doctoral fellow at Moffitt. "Our study found that in cases where less expensive testing may be appropriate, genetic health care providers ordered comprehensive testing for 9.5 percent of participants, compared to 19.4 percent when tests were ordered by other health care providers. At the time of data collection, comprehensive genetic testing cost approximately $4,000, compared to $400 for the less expensive testing."

The findings are important, noted researchers, because costs and quality of care are often the focus of policy-level decisions in health care.

sábado, 7 de junho de 2014

Long-sought molecular map of critical genetic machinery developed

 


Francisco J. Asturias, PhD, associate professor at The Scripps Research Institute, was the senior author of the Cell study.

A team led by researchers at The Scripps Research Institute (TSRI) has used advanced electron microscopy techniques to determine the first accurate structural map of Mediator, one of the largest and most complex "molecular machines" in cells.

Mediator is crucial for the regulation of most genes' activity and works in the cells of all plants and animals. The mapping of its structure -- which includes more than two dozen unique protein subunits -- represents a significant advance in basic cell biology and should shed light on medical conditions involving Mediator's dysfunction, from cancer to inherited developmental disorders.

The finding demonstrates how recently developed molecular imaging methods can be applied to characterize large and important protein complexes.

"Being able to determine how these large molecular machines look, how they're organized and how they move, will be critical for a better understanding of many key processes in cells," said TSRI Associate Professor Francisco J. Asturias, the senior author of the study, which was published on June 5, 2014 by the journal Cell.

A Complex Machine

The detailed map of Mediator comes nearly 20 years after the complex was first described by Stanford University biologist Roger Kornberg and colleagues. Kornberg, whose lab members at the time included Asturias, later won a Nobel Prize for his work on the gene transcription machinery of cells.

This gene transcription machinery evolved to perform one of the most basic and routine functions in biology, namely the copying of the information encoded in the DNA of genes into portable RNA "transcripts" -- some of which stay and work in the cell nucleus, while others exit the nucleus and are translated into proteins.

Each cell has its own pattern of gene transcription activity, determined by a regulatory system in which Mediator plays an indispensable role. The huge Mediator complex enables transcription factors and other regulatory proteins to influence the RNA polymerase II that actually performs the transcription.

To understand precisely how Mediator does its job, scientists have needed an accurate 3-D model of its architecture, including the locations of all its subunit proteins and a description of the different conformations Mediator can adopt to influence interactions between other components of the transcription machinery.

However, Mediator is enormous by biological standards: the version found in yeast has 25 distinct protein subunits and the human version has 30. It is also highly flexible. That combination of large size, high complexity and high flexibility makes it a poor candidate for high resolution imaging methods such as X-ray crystallography or nuclear magnetic resonance spectroscopy.

As a postdoctoral researcher in the Kornberg laboratory in the 1990s, Asturias helped pioneer the use of "single particle" electron microscopy (EM) for the imaging of large transcription complexes such as Mediator. Single-particle EM requires the taking of thousands of separate EM images of a particle of interest -- typically very "noisy" images, which depict a particle in different orientations and perhaps also in a number of different conformations. All these data must be filtered and averaged to reduce the noise and yield useful 3-D pictures. In a 1999 study in Science, Asturias and colleagues used an early form of single-particle EM to determine the first rough structure of the full Mediator complex.

In the decade and a half since then, Asturias's group has continued to use EM techniques to study Mediator. Others have used high-resolution techniques to study individual Mediator subunits or portions of the complex. However, a clear and accurate picture of how the whole structure fits together has been elusive until now.

Turning a Model on its Head

To determine the full structure clearly, Asturias and his colleagues began by producing highly pure quantities of a standard yeast version of Mediator -- the purification process itself being a major challenge. They then used this collection of Mediator particles to record roughly 85,000 EM images, which they categorized according to conformation. Averaging these yielded the clearest 3D model yet of the Mediator structure, to a resolution of about 18 Angstroms (1.8 billionths of a meter).

Using various other biochemical analyses, including the subtraction of different protein subunits to see how the EM images changed, the scientists were able to identify the precise locations of yeast Mediator's 25 protein subunits.

This mapping resulted in a comprehensive revision of the old rough model of Mediator's head-middle-tail structure. "After we located all the protein subunits, we realized that the head module is at the top of Mediator, not the bottom as had been thought," said Kuang-Lei Tsai, a postdoctoral fellow in the Asturias Laboratory, who was first author of the study. "These new data have helped us make sense of many previous biochemical observations."

Asturias and Tsai next collaborated with the laboratory of Joan and Ron Conaway -- Joan is another Kornberg alumnus -- at the Stowers Institute for Medical Research in Kansas City. The Conaway team had been working on human Mediator and now provided pure samples for EM imaging, as well as biochemical analyses of the subunit locations.

This work revealed that human Mediator shares the same broad architecture, implying that this structure has been, for the most part, conserved throughout the billion years of evolution that separate yeast and humans. "Basically the two Mediators have similar overall structure," said Tsai.

In the last part of the study, Asturias and Tsai used the new structural data to show how Mediator likely changes its conformation as it interacts with RNA polymerase on the one hand, and various transcription regulators on the other.

"This study has given us a fairly definitive picture of the Mediator architecture and how the different subunits are organized, so we can start to work towards an atomic resolution model," Asturias said. "We also want to understand better how Mediator interacts with all those other proteins to actually carry out transcription in a regulated manner."

sexta-feira, 6 de junho de 2014

Gene study shows how sheep first separated from goats

 


Scientists at the University of Edinburgh's Roslin Institute have helped to crack the genetic code of sheep. The team were part of the International Sheep Genomics Consortium which sequenced the entire genetic make-up of a texel sheep, the same breed shown in this image. Their findings reveal that sheep became a distinct species from goats around 4 million years ago.

Scientists have cracked the genetic code of sheep to reveal how they became a distinct species from goats around four million years ago.

The study is the first to pinpoint the genetic differences that make sheep different from other animals.

The findings could aid the development of DNA testing to speed-up selective breeding programmes, helping farmers to improve their stocks.

The research identifies the genes that give sheep their fleece and uncovers features of their digestive system, which makes them so well-suited to a diet of low quality grass and other plants.

It also builds the most complete picture yet of sheep's complex biology. Further studies using this resource could reveal new insights to diseases that affect sheep.

Researchers from the University of Edinburgh's Roslin Institute, which receives strategic funding from the Biotechnology and Biological Sciences Research Council, were part of a global team that has decoded the genome sequence -- the entire genetic make-up -- of domestic sheep for the first time.

This team -- the International Sheep Genomics Consortium -- compared the sheep's genes with those of other animals -- including humans, cattle, goats and pigs.

The analysis identifies several genes that are associated with wool production. It also reveals genes that underpin the evolution of the rumen -- a specialised chamber of the stomach that breaks down plant material to make it ready for digestion.

This collaborative study, involving 26 research institutions in eight different countries, was led by researchers from the Commonwealth Scientific and Industrial Research Organisation, Australia; BGI and the Kunming Institute of Zoology, China; Utah State University and Baylor College of Medicine in the US; and The Roslin Institute.

The BBSRC-funded ARK-Genomics facility -- which is part of Edinburgh Genomics at the University of Edinburgh -- provided a substantial body of sequence data, including information on which genes are expressed in a spectrum of 40 different tissues.

The study is published today in the journal Science.

Professor Alan Archibald, Head of Genetics and Genomics at The Roslin Institute, said: "Sheep were one of the first animals to be domesticated for farming and are still an important part of the global agricultural economy. Understanding more about their genetic make-up will help us to breed healthier and more productive flocks."

quarta-feira, 4 de junho de 2014

Courts face challenges when linking genetics to criminal behavior

 

June 4, 2014

Cell Press

Some people may be at increased risk of criminal behavior due to their genes, some say. Such research holds potential for helping judges and juries with some of the difficult decisions they must make, but it also brings a substantial risk of misinterpretation and misuse within the legal system. Experts suggest that addressing these issues will be of critical importance for upholding principles of justice and fairness.


Studies suggest that some people may be at increased risk of criminal behavior due to their genes. Such research holds potential for helping judges and juries with some of the difficult decisions they must make, but it also brings a substantial risk of misinterpretation and misuse within the legal system. Addressing these issues will be of critical importance for upholding principles of justice and fairness, according to an essay being published in the June 4 issue of the Cell Press journal Neuron.

"Genetic evidence, properly used, could assist with judgments regarding appropriate criminal punishments, causes of injury or disability, and other questions before the courts," says author Dr. Paul Appelbaum, who directs Columbia University's Center for Research on Ethical, Legal & Social Implications of Psychiatric, Neurologic & Behavioral Genetics.

Genetic evidence is being offered in criminal trials to suggest that defendants have diminished understanding of or control over their behavior, most often in arguments for mitigating sentences -- especially for defendants facing the death penalty. Genetic evidence may also play an increasing role in civil trials regarding issues such as causation of injury. For example, employers contesting work-related mental disability claims might want claimants to undergo genetic testing to prove that an underlying disorder was not responsible for their impairment.

"The complexity of genetic information and our incomplete understanding of the roots of behavior raise the possibility that genetic evidence will be misused or misunderstood. Hence, care is needed in evaluating the extent to which genetic evidence may have something to add to legal proceedings in a given case," says Dr. Appelbaum.

Moving forward, a number of questions must be addressed. For example, to what extent do specific genetic variants make it more difficult to understand or control one's behavior and what are the biological mechanisms involved? Also, how can we respond to individuals with genetic predispositions to criminal behavior to diminish the risk of recidivism?

Dr. Appelbaum notes that it will be an ongoing challenge for both legal and genetic experts to monitor the use of genetic data in the courts to ensure that the conclusions that are drawn validly reflect the science. Without such efforts, judges and juries may overestimate or underestimate the conclusions that can be drawn from genetic evidence, thus unfairly distorting the legal process.

terça-feira, 3 de junho de 2014

Paired enzyme action in yeast reveals backup system for DNA repair

 

Because such mechanisms are generally conserved throughout evolution, at least in part, researchers say the findings suggest that a similar DNA repair kit may exist in humans and could serve as a target for controlling some cancers and treating a rare, enzyme-linked genetic disorder called Aicardi-Goutieres syndrome. The syndrome, an often fatal neurological condition, is found in only a few families in small towns in Italy, Algeria and Japan, and among North American Cree Indians.

In a report to be published in the journal Nature online June 1, NYU Langone researchers, aided by colleagues at Yale University, found that the paired enzyme action prevents and repairs mistakes made during DNA replication, when molecular subunits known as rNMPs get inserted into DNA. The rNMPs are building blocks of DNA's chemical cousin RNA, which is the key intermediary involved in making all proteins from DNA.

Researchers say while some misplaced rNMPs naturally occur -- and are repaired -- as DNA is replicated during cell growth, enzymes quickly recognize such foreign intruders as lesions. If not removed, such lesions raise the likelihood of mutations in the DNA code, which if allowed to accumulate, create genomic instability in yeast and human cells, and can lead to cell death and cancer-promoting immune reactions.

"Taking our cue from yeast, which shares a third of its genetic make-up with humans, our study shows for the first time that a very robust backup DNA repair mechanism is in place to deal with common rNMP-induced mutations," says senior study investigator and NYU Langone yeast geneticist Hannah Klein, PhD. "Without a robust backup system for DNA repair, cells will die."

Among the study's key findings was that one of the enzymes, Srs2, helps open up the tightly bound, ladder-like yeast DNA structure so that the other enzyme, Exo1, can cleave out any misplaced rNMPs. Such rNMP misinsertions during replication, scientists say, contaminate DNA and are often lethal structural alterations. Both enzymes were previously known to play a role in DNA replication and repair, but the scientists say this is the first evidence of their role in preventing and correcting rNMP-derived mutations.

Moreover, the research team found that the Srs2-Exo1cell-repair mechanism prevents mutations from accelerating in yeast already deficient in a third enzyme coded by the gene RNaseH2. That enzyme serves as the primary removal mechanism for rNMPs during cell growth, a major role in DNA repair. But in yeast deficient in both the RNaseH2 enzyme and Srs2, the number of mutations, chromosome losses, and chromosome breakages rise 10-fold.

According to Dr. Klein, interim chair of biochemistry and molecular pharmacology at NYU Langone, her team's study is also the first to show how Srs2 and Exo1 backs up the routine rNMP maintenance function of the RNaseH2 enzyme, highlighting nature's constant need to balance cell growth, genetic mutation and DNA repair in preventing disease and cell death.

Dr. Klein cautions that while no known human Srs2 counterpart exists, Exo1 is found in human cells, so it is likely that a similar backup DNA repair mechanism exists in people. And if further testing shows that its repair function can be manipulated in humans, the enzyme mechanism could be used as a basis to stall or reverse cancers derived from RNaseH2 mutations. Dr. Klein says breaking down how tumors develop in RNaseH2-deficient yeast cells is critical to formulating and testing potential treatments for people.

Other research has implicated overproduction of RNase H2 as one of several genetic features of many cancers, including cancers of the bladder, brain, breast, head, and neck squamous cell carcinomas, as well as leukemias (T- and B-cell acute lymphoblastic leukemia and acute myeloid leukemia), melanomas, and seminomas.

Even more specifically, she says, the enzyme repair mechanism could potentially be used to decipher and counteract the root causes of RNaseH2 enzyme deficiency, which in humans is known to be one of the main hereditary signatures behind Aicardi -Goutieres syndrome. The syndrome causes spinal inflammation and brain shrinkage, fatally stalling physical and mental development in early childhood. Although rare and currently untreatable, the disease afflicts hundreds in isolated communities where inbreeding among families has occurred and when both parents have RNaseH2 or other Aicardi -Goutieres-related mutations.

For the study, lead investigator and fellow yeast geneticist Catherine Potenski, PhD, monitored how various mutant yeast strains grew in the laboratory, including those deficient in the RNaseH2 enzyme and Srs2. (Dr. Klein's lab in the late 1980s was the first to isolate RNaseH2 mutations in yeast.)

Dr. Potenski, a postdoctoral fellow at NYU Langone, says yeast strains deficient in both enzymes accumulated mutations and did not grow well, while those depleted of only the RNaseH2 enzyme, were able to minimize mutations and continue growing. However, in experiments with Exo1, its removal spiked mutations in RNaseH2-deficient strains, while depletion of Srs2 had no worsening effect. This evidence confirmed to researchers that Srs2 and Exo1 acted together to prevent mutations in RNaseH2-deficient cells.

Analysis by colleagues at Yale later confirmed the linked action between Srs2 and Exo1, showing how Srs2 stimulated Exo1 to act on yeast DNA, allowing for the cleaving and repair of rNMP lesions.

Dr. Potenski says her latest studies of Srs2, Exo1, and RNaseH2 enzymes should also serve as a reminder to other researchers that known enzymes may have many roles in the cell life cycle, some of which are not yet known, and that even more backup roles could be found.

Dr. Potenski says the team next plans to investigate what other biological factors may act on Exo1, as a possible third backup repair mechanism, and to investigate what factors might trigger RNaseH2 mutations more prone to lead to cancer.

domingo, 1 de junho de 2014

Prevalence of new genetic driver in lung cancer shown in study

 

May 31, 2014

University of Colorado Cancer Center

A line has been drawn from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. "Everything we know about lung cancer points to the idea that when we find one of these genetic drivers and can target it with a drug, patients will respond and tend to have a good amount of time on drug before it becomes ineffective. Obviously we can't guarantee the effectiveness of targeting the NTRK1 mutation at this point, but everything we know about these kinds of genes makes us extremely hopeful," says one researcher.


A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. The current study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1% percent of patients testing positive. This and other work from Dr. Doebele's group forms the basis of a phase 1 clinical trial targeting NTRK1 mutations in advanced solid tumors (NCT02122913).

"Everything we know about lung cancer points to the idea that when we find one of these genetic drivers and can target it with a drug, patients will respond and tend to have a good amount of time on drug before it becomes ineffective. Obviously we can't guarantee the effectiveness of targeting the NTRK1 mutation at this point, but everything we know about these kinds of genes makes us extremely hopeful," says Robert C. Doebele, MD, PhD, investigator at the CU Cancer Center and associate professor of Medical Oncology at the CU School of Medicine.

Previous work in collaboration with Pasi A. Jänne, MD, PhD from the Dana-Farber Cancer Institute, examined lung cancer tumor samples from 36 "pan-negative" patients, meaning that no other driver oncogene had been identified. Next-gen sequencing at Foundation Medicine (Cambridge, MA) identified NTRK1 gene fusions as the potential driver in two of these samples.

Doebele and colleagues took the finding back to CU labs, where Marileila Varella-Garcia, PhD, developed a specific test for NTRK1 fusions based on fluorescence in situ hybridization (FISH), similar to what is currently used for ALK, ROS1 and RET fusions. This test would allow rapid detection of NRTK1 oncogenes in patient samples. "But no one had ever looked for NTRK1 mutations in a large series of unbiased patient samples," Doebele says. "The point of this study was to get a better sense of how many lung cancer patients are likely to be positive for NTRK1 mutations and what these patients are likely to look like."

Of 450 evaluated patient samples of non-small cell lung cancer, 5 tested "positive" and another 12 are considered suspicious for the mutation. Next generation sequencing studies revealed 5 previously undescribed NTRK1 mutations. Ongoing work seeks to tease apart the subtleties of diagnosis to further refine the criteria used to decide which tumors are truly created by the NTRK1 mutation.

Again, just as the FDA-approved drug crizotinib targets ALK fusions in an affected subset of lung cancer, the goal of the current line of research is to identify patients whose cancers are caused by NTRK1 and similarly target these patients with a drug that silences the problem gene. Toward that goal, Array BioPharma (Boulder, CO) provided candidate drugs to inhibit mutated NTRK1. Loxo Oncology, Inc. has managed further testing of the leading drug candidate, now known as LOXO-101. A phase 1a/1b clinical trial of the drug in advanced solid tumors is now recruiting patients.

"We found the mutation in a patient sample in 2012, published a manuscript in 2013 describing NTRK1 as a driver of lung cancer, and now here we are in May 2014 laying the groundwork for a clinical trial of drugs targeting this mutation," Doebele says. "Having seen this approach work well with other mutations in the past, the team is optimistic that this research could help control another important subset of lung cancers."


Story Source:

The above story is based on materials provided by University of Colorado Cancer Center. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.

terça-feira, 27 de maio de 2014

How DNA is 'edited' to correct genetic diseases

 

May 26 / 2014

University of Bristol

A major step forward in our understanding of how enzymes 'edit' genes has been made by an international team of researchers, paving the way for correcting genetic diseases in patients. Researchers have observed the process by which a class of enzymes called CRISPR -- pronounced 'crisper' -- bind and alter the structure of DNA. The results provide a vital piece of the puzzle if these genome editing tools are ultimately going to be used to correct genetic diseases in humans.


An illustration of DNA attached to magnetic beads, as used in the single molecule microscope.

An international team of scientists has made a major step forward in our understanding of how enzymes 'edit' genes, paving the way for correcting genetic diseases in patients.

Researchers at the Universities of Bristol, Münster and the Lithuanian Institute of Biotechnology have observed the process by which a class of enzymes called CRISPR -- pronounced 'crisper' -- bind and alter the structure of DNA.

The results, published in the Proceedings of the National Academy of Sciences (PNAS), provide a vital piece of the puzzle if these genome editing tools are ultimately going to be used to correct genetic diseases in humans.

CRISPR enzymes were first discovered in bacteria in the 1980s as an immune defence used by bacteria against invading viruses. Scientists have more recently shown that one type of CRISPR enzyme -- Cas9 -- can be used to edit the human genome -- the complete set of genetic information for humans.

These enzymes have been tailored to accurately target a single combination of letters within the three billion base pairs of the DNA molecule. This is the equivalent of correcting a single misspelt word in a 23-volume encyclopaedia.

To find this needle in a haystack, CRISPR enzymes use a molecule of RNA -- a nucleic acid similar in structure to DNA. The targeting process requires the CRISPR enzymes to pull apart the DNA strands and insert the RNA to form a sequence-specific structure called an 'R-loop'.

The global team tested the R-loop model using specially modified microscopes in which single DNA molecules are stretched in a magnetic field. By altering the twisting force on the DNA, the researchers could directly monitor R-loop formation events by individual CRISPR enzymes.

This allowed them to reveal previously hidden steps in the process and to probe the influence of the sequence of DNA bases.

Professor Mark Szczelkun, from Bristol University's School of Biochemistry, said: "An important challenge in exploiting these exciting genome editing tools is ensuring that only one specific location in a genome is targeted.

"Our single molecule assays have led to a greater understanding of the influence of DNA sequence on R-loop formation. In the future this will help in the rational re-engineering of CRISPR enzymes to increase their accuracy and minimise off-target effects. This will be vital if we are to ultimately apply these tools to correct genetic diseases in patients."

The work was funded at the University of Bristol by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Wellcome Trust.


Story Source:

The above story is based on materials provided by University of Bristol. Note: Materials may be edited for content and length.


Journal Reference:

  1. Mark D. Szczelkuna, Maria S. Tikhomirovab, Tomas Sinkunasd, Giedrius Gasiunasd, Tautvydas Karvelisd, Patrizia Pscherac, Virginijus Siksnysd and Ralf Seidel. Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes. PNAS, May 2014

sábado, 24 de maio de 2014

Genes discovered linking circadian clock with eating schedule

 

May 22 / 2014

Salk Institute for Biological Studies

For most people, the urge to eat a meal or snack comes at a few, predictable times during the waking part of the day. But for those with a rare syndrome, hunger comes at unwanted hours, interrupts sleep and causes overeating. "We really never expected that we would be able to decouple the sleep-wake cycle and the eating cycle," says the senior study author. "It opens up a whole lot of future questions about how these cycles are regulated."


Caption: Mice with a mutation in the PER2 gene (top right) have an altered sleep cycle, while those with a mutation in the PER1 gene (bottom right) have an abnormal eating schedule.

For most people, the urge to eat a meal or snack comes at a few, predictable times during the waking part of the day. But for those with a rare syndrome, hunger comes at unwanted hours, interrupts sleep and causes overeating.

Now, Salk scientists have discovered a pair of genes that normally keeps eating schedules in sync with daily sleep rhythms, and, when mutated, may play a role in so-called night eating syndrome. In mice with mutations in one of the genes, eating patterns are shifted, leading to unusual mealtimes and weight gain. The results were published in this month's Cell Reports.

"We really never expected that we would be able to decouple the sleep-wake cycle and the eating cycle, especially with a simple mutation," says senior study author Satchidananda Panda, an associate professor in Salk's Regulatory Biology Laboratory. "It opens up a whole lot of future questions about how these cycles are regulated."

More than a decade ago, researchers discovered that individuals with an inherited sleep disorder often carry a particular mutation in a protein called PER2. The mutation is in an area of the protein that can be phosphorylated -- the ability to bond with a phosphate chemical that changes the protein's function. Humans have three PER, or period, genes, all thought to play a role in the daily circadian clock and all containing the same phosphorylation spot.

The Salk scientists joined forces with a Chinese team led by Ying Xu of Nanjing University to test whether mutations in the equivalent area of PER1 would have the same effect as those in PER2 that caused the sleep disorder. So they bred mice to lack the mouse period genes, and added in a human PER1 or PER2 with a mutation in the phosphorylation site. As expected, mice with a mutated PER2 had sleep defects, dozing off earlier than usual. The same wasn't true for PER1 mutations though.

"In the mice without PER1, there was no obvious defect in their sleep-wake cycles," says Panda. "Instead, when we looked at their metabolism, we suddenly saw drastic changes."

Mice with the PER1 phosphorylation defects ate earlier than other mice -- causing them to wake up and snack before their sleep cycle was over -- and ate more food throughout their normal waking period. When the researchers looked at the molecular details of the PER1 protein, they found that the mutated PER1 led to lower protein levels during the sleeping period, higher levels during the waking period, and a faster degradation of protein whenever it was produced by cells.

Panda and his colleagues hypothesize that normally, PER1 and PER2 are kept synchronized since they have identical phosphorylation sites -- they are turned on and off at the same times, keeping sleep and eating cycles aligned. But a mutation in one of the genes could break this link, and cause off-cycle eating or sleeping.

"For a long time, people discounted night eating syndrome as not real," says Panda. "These results in mice suggest that it could actually be a genetic basis for the syndrome." The researchers haven't yet tested, however, whether any humans with night eating syndrome have mutations in PER1.

When Panda and Xu's team restricted access to food, providing it only at the mice's normal meal times, they found that even with a genetic mutation in PER1, mice could maintain a normal weight. Over a 10-week follow-up, these mice -- with a PER1 mutation but timed access to food -- showed no differences to control animals. This tells the researchers that the weight gain caused by PER1 is entirely caused by meal mistiming, not other metabolic defects.

Next, they hope to study exactly how PER1 controls appetite and eating behavior -- whether its molecular actions work through the liver, fat cells, brain or other organs.


Story Source:

The above story is based on materials provided by Salk Institute for Biological Studies. Note: Materials may be edited for content and length.


Journal Reference:

  1. Zhiwei Liu, Moli Huang et al. PER1 Phosphorylation Specifies Feeding Rhythm in Mice. Cell Reports, May 2014 DOI: 10.1016/j.celrep.2014.04.032

sexta-feira, 23 de maio de 2014

Gene behind unhealthy adipose tissue identified

 

May 22 / 2014

Karolinska Institutet

A gene driving the development of pernicious adipose tissue in humans has been identified by researchers for the first time. The findings imply that the gene may constitute a risk factor promoting the development of insulin resistance and type 2 diabetes. "Our findings represent an important step forward in the understanding of how adipose tissue links to the development of metabolic disease," comments one of the principal investigators.


Dr. Peter Arner, Ph.D., is a Professor of Medicine at Karolinska Institutet in Stockholm, Sweden.

Researchers at Karolinska Institutet in Sweden have for the first time identified a gene driving the development of pernicious adipose tissue in humans. The findings imply, which are published in the scientific journal Cell Metabolism, that the gene may constitute a risk factor promoting the development of insulin resistance and type 2 diabetes.

Adipose tissue can expand in two ways: by increasing the size and/or the number of the fat cells. It is well established that subjects with few but large fat cells, so-called hypertrophy, display an increased risk of developing type 2-diabetes. In the current study, researchers identified a gene, EBF1, which according to these new findings drive the development of the unhealthy adipose tissue. This gene encodes a protein that controls a set of other genes, a so-called transcription factor, and regulates the formation of new fat cells as well as their metabolic function.

The investigators compared adipose tissue from subjects with small or large fat cells and found that EBF1 was closely linked to hypertrophy. Individuals with large fat cells had markedly lower EBF1 expression in their adipose tissue, displayed altered lipid mobilisation and were insulin resistant. Insulin resistance -- a condition characterised by reduced cellular response to the hormone insulin that is released when the blood glucose levels rise after a meal -- is an important causal factor underlying the increased risk of diabetes in individuals with hypertrophic adipose tissue. Insulin resistance leads to increased circulating levels of glucose and lipids in the blood.

In collaboration with Professor Mark C. Horowitz at Yale School of Medicine, U.S. the researchers also investigated genetically modified mice expressing lower levels of the murine variant of the human EBF1-gene. It turned out that these mice developed adipose hypertrophy and displayed increased lipid mobilisation from fat cells. When the mice were put on high-fat diet they became insulin resistant.

"Our findings represent an important step forward in the understanding of how adipose tissue links to the development of metabolic disease," comments Professor Peter Arner, one of the principal investigators at Karolinska Institutet along with Hui Gao, Niklas Mejhert and Mikael Rydén. "This is the first time someone has identified a gene which may cause malfunctioning adipose tissue in (hu)man. In the future, it might be possible to develop drugs that improve EBF1 function in adipose tissue, which could be used to treat type 2-diabetes."


Story Source:

The above story is based on materials provided by Karolinska Institutet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hui Gao, Niklas Mejhert, Jackie A. Fretz, Erik Arner, Silvia Lorente-Cebrián, Anna Ehrlund, Karin Dahlman-Wright, Xiaowei Gong, Staffan Strömblad, Iyadh Douagi, Jurga Laurencikiene, Ingrid Dahlman, Carsten O. Daub, Mikael Rydén, Mark C. Horowitz, Peter Arner. Early B Cell Factor 1 Regulates Adipocyte Morphology and Lipolysis in White Adipose Tissue. Cell Metabolism, 2014; DOI: 10.1016/j.cmet.2014.03.032

Common obesity gene contributes to weight gain

 

 

May 22 / 2014

Columbia University Medical Center

A gene commonly linked to obesity -— FTO —- contributes to weight gain, researchers have demonstrated. The study shows that variations in FTO indirectly affect the function of the primary cilium, a little-understood hair-like appendage on brain and other cells. Specific abnormalities of cilium molecules, in turn, increase body weight, in some instances, by affecting the function of receptors for leptin, a hormone that suppresses appetite. The findings, made in mice, suggest that it might be possible to modify obesity through interventions that alter the function of the cilium.


Microscopic image of brain cells (stained purple). A new study shows how FTO, a gene commonly associated with obesity, contributes to weight gain. Changes in this gene indirectly affect the function of the primary cilium (shown here in green) — a hair-like appendage found on brain and other cells. Irregularities in the cilium, in turn, can affect receptors for leptin, which suppresses appetite.

Researchers have discovered how a gene commonly linked to obesity -- FTO -- contributes to weight gain. The study shows that variations in FTO indirectly affect the function of the primary cilium, a little-understood hair-like appendage on brain and other cells. Specific abnormalities of cilium molecules, in turn, increase body weight, in some instances, by affecting the function of receptors for leptin, a hormone that suppresses appetite. The findings, made in mice, suggest that it might be possible to modify obesity through interventions that alter the function of the cilium, according to scientists at Columbia University Medical Center (CUMC).

"If our findings are confirmed, they could explain how common genetic variants in the gene FTO affect human body weight and lead to obesity," said study leader Rudolph L. Leibel, MD, the Christopher J. Murphy Memorial Professor of Diabetes Research, professor of pediatrics and medicine, and co-director of the Naomi Berrie Diabetes Center at CUMC. "The better we can understand the molecular machinery of obesity, the better we will be able to manipulate these mechanisms and help people lose weight."

The study was published on May 6 in the online edition of Cell Metabolism.

Since 2007, researchers have known that common variants in the fat mass and obesity-associated protein gene, also known as FTO, are strongly associated with increased body weight in adults. But it was not understood how alterations in FTO might contribute to obesity. "Studies have shown that knocking out FTO in mice doesn't necessarily lead to obesity, and not all humans with FTO variants are obese," said Dr. Leibel. "Something else is going on at this location that we were missing."

In experiments with mice, the CUMC team observed that as FTO expression increased or decreased, so did the expression of a nearby gene, RPGRIP1L. RPGRIP1L is known to play a role in regulating the primary cilium. "Aberrations in the cilium have been implicated in rare forms of obesity," said Dr. Leibel. "But it wasn't clear how this structure might be involved in garden-variety obesity."

Dr. Leibel and his colleague, George Stratigopoulos, PhD, associate research scientist, hypothesized that common FTO variations in noncoding regions of the gene do not change its primary function, which is to produce an enzyme that modifies DNA and RNA. Instead, they suspected that FTO variations indirectly affect the expression of RPGRIP1L. "When Dr. Stratigopoulos analyzed the sequence of FTO's intron -- its noncoding, or nonprotein-producing, portion -- we found that it serves as a binding site for a protein called CUX1," said Dr. Leibel. "CUX1 is a transcription factor that modifies the expression of RPGRIP1L."

Next, Dr. Stratigopoulos set out to determine whether RPGRIP1L plays a role in obesity. He created mice lacking one of their two RPGRIP1L genes, in effect, reducing but not eliminating the gene's function. (Mice that lack both copies of the gene have several serious defects that would obscure the effects on food intake.) Mice with one copy of RPGRIP1L had a higher food intake, gained significantly more weight, and had a higher percentage of body fat than controls.

In a subsequent experiment, the CUMC team found that RPGRIP1L-deficient mice had impaired leptin signaling. "The receptors didn't convene properly on the cell surface around the base of cilium," said Dr. Leibel. "RPGRIP1L appears to play a role in getting leptin receptors to form clusters, where they are more efficient in signaling."

"Overall," said Dr. Leibel, "our findings open a window onto the possible role of the primary cilium in common forms of obesity."

The CUMC team is now conducting studies to learn more about the various components of the FTO- RPGRIP1L pathway, which ciliary proteins are affected by changes in this pathway, and how these proteins mediate actions of leptin receptors.


Story Source:

The above story is based on materials provided by Columbia University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. George Stratigopoulos, Jayne F. Martin Carli, Diana R. O’Day, Liheng Wang, Charles A. LeDuc, Patricia Lanzano, Wendy K. Chung, Michael Rosenbaum, Dieter Egli, Daniel A. Doherty, Rudolph L. Leibel. Hypomorphism for RPGRIP1L, a Ciliary Gene Vicinal to the FTO Locus, Causes Increased Adiposity in Mice. Cell Metabolism, 2014; 19 (5): 767 DOI: 10.1016/j.cmet.2014.04.009

quinta-feira, 22 de maio de 2014

In your genes: Family history reveals predisposition to multiple diseases

 

May 21, 2014

University of Melbourne

Nine simple questions can be used to identify people who may be at increased risk of various cancers, heart disease and diabetes because of their family history of these conditions, research shows. The family history screening questionnaire can be used to provide insight into people's susceptibility to breast, ovarian, bowel and prostate cancer, melanoma, ischaemic heart disease and type 2 diabetes.


Researchers have identified nine simple questions that can be used to identify people who may be at increased risk of various cancers, heart disease and diabetes because of their family history of these conditions.

The family history screening questionnaire can be used to provide insight into people's susceptibility to breast, ovarian, bowel and prostate cancer, melanoma, ischemic heart disease and type 2 diabetes.

These findings will lead to greater insight into the process of preventative treatment for cancer in primary care and provide a cost-effective intervention for tailored disease prevention in Australian primary care..

Lead researcher Professor of Primary Care Cancer Research at the University of Melbourne Jon Emery said this research is the first of its kind to validate the family history screening questionnaire as a tool to cover multiple conditions.

"No brief tool has been developed to cover a range of conditions in primary care that has been validated to the same extent as ours."

"This finding could be used as a screening tool in general practice to identify people who need a more detailed discussion about their family history of cancer, diabetes or heart disease," Professor Emery said.

"Some people may require referral to a genetics clinic to discuss genetic testing, many more may require earlier cancer screening and lifestyle management," he said.

Family medical history remains the most relevant genetic risk took in use in clinical practice.

Evidence suggests that having knowledge of a family history of a specific condition is associated with improved uptake of a range of disease-preventative activities, such as cancer screening and reduced sun exposure.


Story Source:

The above story is based on materials provided by University of Melbourne. Note: Materials may be edited for content and length.

sexta-feira, 2 de maio de 2014

The Experiment

 

By Christina Larson

Until recently, Kunming, capital of China’s southwestern Yunnan province, was known mostly for its palm trees, its blue skies, its laid-back vibe, and a steady stream of foreign backpackers bound for nearby mountains and scenic gorges. But Kunming’s reputation as a provincial backwater is rapidly changing. On a plot of land on the outskirts of the city—wilderness 10 years ago, and today home to a genomic research facility—scientists have performed a provocative experiment. They have created a pair of macaque monkeys with precise genetic mutations.

Last November, the female monkey twins, Mingming and Lingling, were born here on the sprawling research campus of Kunming Biomedical International and its affiliated Yunnan Key Laboratory of Primate Biomedical Research. The macaques had been conceived via in vitro fertilization. Then scientists used a new method of DNA engineering known as CRISPR to modify the fertilized eggs by editing three different genes, and they were implanted into a surrogate macaque mother. The twins’ healthy birth marked the first time that CRISPR has been used to make targeted genetic modifications in primates—potentially heralding a new era of biomedicine in which complex diseases can be modeled and studied in monkeys.

CRISPR, which was developed by researchers at the University of California, Berkeley, Harvard, MIT, and elsewhere over the last several years, is already transforming how scientists think about genetic engineering, because it allows them to make changes to the genome precisely and relatively easily (see “Genome Surgery,” March/April). The goal of the experiment at Kunming is to confirm that the technology can create primates with multiple mutations, explains Weizhi Ji, one of the architects of the experiment.

Ji began his career at the government-affiliated Kunming Institute of Zoology in 1982, focusing on primate reproduction. China was “a very poor country” back then, he recalls. “We did not have enough funding for research. We just did very simple work, such as studying how to improve primate nutrition.” China’s science ambitions have since changed dramatically. The campus in Kunming boasts extensive housing for monkeys: 75 covered homes, sheltering more than 4,000 primates—many of them energetically swinging on hanging ladders and scampering up and down wire mesh walls. Sixty trained animal keepers in blue scrubs tend to them full time.

The lab where the experiment was performed includes microinjection systems, which are microscopes pointed at a petri dish and two precision needles, controlled by levers and dials. These are used both for injecting sperm into eggs and for the gene editing, which uses “guide” RNAs that direct a DNA-cutting enzyme to genes. When I visited, a young lab technician was intently focused on twisting dials to line up sperm with an egg. Injecting each sperm takes only a few seconds. About nine hours later, when an embryo is still in the one-cell stage, a technician will use the same machine to inject it with the CRISPR molecular components; again, the procedure takes just a few seconds.

During my visit in late February, the twin macaques were still only a few months old and lived in incubators, monitored closely by lab staff. Indeed, Ji and his coworkers plan to continue to closely watch the monkeys to detect any consequences of the pioneering genetic modifications.

 

The Impact

By Amanda Schaffer

The new genome-editing tool called CRISPR, which researchers in China used to genetically modify monkeys, is a precise and relatively easy way to alter DNA at specific locations on chromosomes. In early 2013, U.S. scientists showed it could be used to genetically engineer any type of animal cells, including human ones, in a petri dish. But the Chinese researchers were the first to demonstrate that this approach can be used in primates to create offspring with specific genetic alterations.

“The idea that we can modify primates easily with this technology is powerful,” says Jennifer Doudna, a professor of molecular and cell biology at the University of California, Berkeley, and a developer of CRISPR. The creation of primates with intentional gene alterations could lead to powerful new ways to study complex human diseases. It also poses new ethical dilemmas. From a technical perspective, the Chinese primate research suggests that scientists could probably alter fertilized human eggs with CRISPR; if monkeys are any guide, such eggs could grow to be genetically modified babies. But “whether that would be a good idea is a much harder question,” says Doudna.

The prospect of designer babies remains remote and far from the minds of most researchers developing CRISPR. Far more imminent are the potential opportunities to create animals with mutations linked to human disorders. Experimenting with primates is expensive and can raise concerns about animal welfare, says Doudna. But the demonstration that CRISPR works in monkeys has gotten “a lot of people thinking about cases where primate models may be important.”

At the top of that list is the study of brain disorders. Robert Desimone, director of MIT’s McGovern Institute for Brain Research, says that there is “quite a bit of interest” in using CRISPR to generate monkey models of diseases like autism, schizophrenia, Alzheimer’s disease, and bipolar disorder. These disorders are difficult to study in mice and other rodents; not only do the affected behaviors differ substantially between these animals and humans, but the neural circuits involved in the disorders can be different. Many experimental psychiatric drugs that appeared to work well in mice have not proved successful in human trials. As a result of such failures, many pharmaceutical companies have scaled back or abandoned their efforts to develop treatments.

Primate models could be especially helpful to researchers trying to make sense of the growing number of mutations that genetic studies have linked to brain disorders. The significance of a specific genetic variant is often unclear; it could be a cause of a disorder, or it could just be indirectly associated with the disease. CRISPR could help researchers tease out the mutations that actually cause the disorders: they would be able to systematically introduce the suspected genetic variants into monkeys and observe the results. CRISPR is also useful because it allows scientists to create animals with different combinations of mutations, in order to assess which onesor which combinations of themmatter most in causing disease. This complex level of manipulation is nearly impossible with other methods.

Guoping Feng, a professor of neuroscience at MIT, and Feng Zhang, a colleague at the Broad Institute and McGovern Brain Institute who showed that CRISPR could be used to modify the genomes of human cells, are working with Chinese researchers to create macaques with a version of autism. They plan to mutate a gene called SHANK3 in fertilized eggs, producing monkeys that can be used to study the basic science of the disorder and test possible drug treatments. (Only a small percentage of people with autism have the SHANK3 mutation, but it is one of the few genetic variants that lead to a high probability of the disorder.)

The Chinese researchers responsible for the birth of the genetically engineered monkeys are still focusing on developing the technology, says Weizhi Ji, who helped lead the effort at the Yunnan Key Laboratory of Primate Biomedical Research in Kunming. However, his group hopes to create monkeys with Parkinson’s, among other brain disorders. The aim would be to look for early signs of the disease and study the mechanisms that allow it to progress.

The most dramatic possibility raised by the primate work, of course, would be using CRISPR to change the genetic makeup of human embryos during in vitro fertilization. But while such manipulation should be technically possible, most scientists do not seem eager to pursue it.

Indeed, the safety concerns would be daunting. When you think about “messing with a single cell that is potentially going to become a living baby,” even small errors or side effects could turn out to have enormous consequences, says Hank Greely, director of the Center for Law and the Biosciences at Stanford. And why even bother? For most diseases with simple genetic causes, it wouldn’t be worthwhile to use CRISPR; it would make more sense for couples to “choose a different embryo that doesn’t have the disease,” he says. This is already possible as part of in vitro fertilization, using a procedure called preimplantation genetic diagnosis.

It’s possible to speculate that parents might wish to alter multiple genes in order to reduce children’s risk, say, of heart disease or diabetes, which have complex genetic components. But for at least the next five to 10 years, that, says Greely, “just strikes me as borderline crazy, borderline implausible.” Many, if not most, of the traits that future parents might hope to alter in their kids may also be too complex or poorly understood to make reasonable targets for intervention. Scientists don’t understand the genetic basis, for instance, of intelligence or other higher-order brain functions—and that is unlikely to change for a long time.

Ji says creating humans with CRISPR-edited genomes is “very possible,” but he concurs that “considering the safety issue, there would still be a long way to go.” In the meantime, his team hopes to use genetically modified monkeys to “establish very efficient animal models for human diseases, to improve human health in the future.”

Technology Review - La rivista del MIT per l'innovazione - Mozilla Firefox 2014-02-27 12.32.02

Press Release: Computational Method Dramatically Speeds Up Estimates of Gene Expression, CMU, UMD Researchers Report

 

"Sailfish" Method Could Pay Dividends as Genomic Medicine Expands

Contact: Byron Spice  / 412-268-9068  / bspice@cs.cmu.edu

Carl KingsfordPITTSBURGH—With gene expression analysis growing in importance for both basic researchers and medical practitioners, researchers at Carnegie Mellon University and the University of Maryland have developed a new computational method that dramatically speeds up estimates of gene activity from RNA sequencing (RNA-seq) data.

With the new method, dubbed Sailfish after the famously speedy fish, estimates of gene expression that previously took many hours can be completed in a few minutes, with accuracy that equals or exceeds previous methods. The researchers' report on their new method is being published online April 20 by the journal Nature Biotechnology.

Gigantic repositories of RNA-seq data now exist, making it possible to re-analyze experiments in light of new discoveries. "But 15 hours a pop really starts to add up, particularly if you want to look at 100 experiments," said Carl Kingsford, an associate professor in CMU's Lane Center for Computational Biology. "With Sailfish, we can give researchers everything they got from previous methods, but faster."

Though an organism's genetic makeup is static, the activity of individual genes varies greatly over time, making gene expression an important factor in understanding how organisms work and what occurs during disease processes. Gene activity can't be measured directly, but can be inferred by monitoring RNA, the molecules that carry information from the genes for producing proteins and other cellular activities.

SailfishRNA-seq is a leading method for producing these snapshots of gene expression; in genomic medicine, it has proven particularly useful in analyzing certain cancers.

The RNA-seq process results in short sequences of RNA, called "reads." In previous methods, the RNA molecules from which they originated could be identified and measured only by painstakingly mapping these reads to their original positions in the larger molecules.

But Kingsford, working with Rob Patro, a post-doctoral researcher in the Lane Center, and Stephen M. Mount, an associate professor in Maryland's Department of Cell Biology and Molecular Genetics and its Center for Bioinformatics and Computational Biology, found that the time-consuming mapping step could be eliminated. Instead, they found they could allocate parts of the reads to different types of RNA molecules, much as if each read acted as several votes for one molecule or another.

Without the mapping step, Sailfish can complete its RNA analysis 20-30 times faster than previous methods.

This numerical approach might not be as intuitive as a map to a biologist, but it makes perfect sense to a computer scientist, Kingsford said. Moreover, the Sailfish method is more robust — better able to tolerate errors in the reads or differences between individuals' genomes. These errors can prevent some reads from being mapped, he explained, but the Sailfish method can make use of all the RNA read "votes," which improves the method's accuracy.

The Sailfish code has been released and is available for download at http://www.cs.cmu.edu/~ckingsf/software/sailfish/.

This work was supported in part by the National Science Foundation and the National Institutes of Health.

Carl Kingsford (pictured above), an associate professor in CMU's Lane Center for Computational Biology, said the new computational method, called Sailfish, can give researchers everything they got from previous methods, but faster. With Sailfish estimates of gene expression that previously took many hours can be completed in a few minutes, with accuracy that equals or exceeds previous methods.

Press Release- Computational Method Dramatically Speeds Up Estimates of Gene Expression, CMU, UMD Researchers Report-Carnegie Mellon News - Carnegie Mellon University 2014-05-02 04-10-50

sábado, 26 de abril de 2014

Stanford researchers create a new technique to study how we inherit disease

 

By sequencing the DNA of the offspring, scientists can now determine which traits came from each parent during the gene-shuffling process of fertilization.

Human reproduction is simple. A sperm cell carries the man’s genome into the egg. There, during fertilization, male and female genomes commingle in a way that fuses different traits from each parent into the DNA blueprint for a new human being.

Parents aren’t perfect. Their genomes may contain disease-causing mutations. Nature tries to protect offspring by gene-mixing. This way if one parent passes on a defective mutation, the other has a chance to contribute a working copy.

Until now, however, there hasn’t been an easy way to determine whether an offspring inherited a good working copy of a gene or two defective mutations, a scenario that could cause disease or illness.

In a recent paper in Nature Biotechnology, a research team led by Stanford scientists and engineers describes a new process that can analyze an offspring’s DNA and reveal which specific genes were inherited from each parent.

“If you sequence the child you can now tell what traits they inherited from their parents,” said Michael Snyder, professor and chair of genetics at Stanford and principal author of the study, which was co-authored by Volodymyr Kuleshov, a doctoral student in computer science at Stanford.

x chromosome image

The human genetic code is written on DNA, which is packaged into large molecules called chromosomes. Chromosomes from the mother and father commingle to form a child. Depicted here in pink and blue are the chromosomes of the mother and father. Stanford scientists have developed a way to deduce the genetic sequence of each parent's chromosome by performing a new type of analysis on a sample of DNA taken from their offspring.

DNA is made up of four chemicals – A, T, G and C – strung in a specific order. A person has 6 billion of these chemicals assembled into 46 chromosomes, 23 each from mother and father.

When scientists sequence a person’s genome, they break the DNA into small pieces to determine the order of the A, T, G and Cs.

The problem is that current process doesn’t reveal all the information needed to ascertain which parts of a person’s genome come from which parent. Important variants could come from either the mother’s or the father’s chromosomes.

The Stanford team used several innovations to provide this missing information on parental inheritance.

First the researchers chopped the DNA into blocks 10,000 letters long. Since modern sequencers can’t directly read blocks that long, the researchers then cut these long segments into shorter snippets of 100 letters – tagging each snippet so that they knew from which mega block it came.

Using a computer analysis, the researchers determined which genetic variants from the offspring’s DNA were linked together in 10,000 letter blocks. Finally their algorithms reassembled these longer blocks into two complete sequences, one for each parent’s chromosomes.

The Stanford process can reveal whether individuals have one good copy of a gene or two bad copies – without sequencing the DNA of parents. Knowing this inheritance information is crucial in determining which DNA changes may cause disease. The new process also allows scientists and treating physicians to collect this information more quickly and accurately than previous methods, according to the report in Nature Biotechnology.

Because of its speed, precision and utility, the Stanford approach is being marketed as a commercial process by the biotechnology firm Illumina.

Other co-authors are genetics researchers Rui Chen and Zhihai Ma, who explored additional uses of these tools; Illumina scientists Dimitry Pushkarev and Michael Kertesz, who developed the DNA preparation processes, and their colleague Tim Blauwkamp, who prepared the samples for this experiment; and Dan Xie, a postdoctoral scholar at Stanford who was involved in the computational analyses.

The experiments were funded by grants from the National Institutes of Health and the Genetics Department of Stanford University.

Tom Abate is the Associate Director of Communications at Stanford Engineering.

Inspired by a music box, Stanford bioengineer creates $5 chemistry set - Engineering 2014-04-19 02-32-13